Cejalvo Juan Miguel, Falato Claudette, Villanueva Lorea, Tolosa Pablo, González Xavier, Pascal Mariona, Canes Jordi, Gavilá Joaquín, Manso Luis, Pascual Tomás, Prat Aleix, Salvador Fernando
Hospital Clínico Universitario de Valencia, INCLIVA (Instituto de investigación sanitaria) and CIBERONC, Valencia, Spain; SOLTI Cancer Research Group, Barcelona, Spain.
SOLTI Cancer Research Group, Barcelona, Spain; August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden.
Cancer Treat Rev. 2022 May;106:102392. doi: 10.1016/j.ctrv.2022.102392. Epub 2022 Apr 8.
Immunotherapy has revolutionized the oncology field during the last years, mainly with the introduction of immune checkpoint inhibitors in the clinical routine. Despite the recent approval of these drugs for the treatment of triple-negative breast cancer, most breast cancer patients cannot benefit from immunotherapy as most tumors are not considered immunoreactive. Therefore, new strategies must be developed to bring immunotherapy closer to breast cancer patients. The introduction of oncolytic viruses in the immuno-oncology field has shown promising results in cancer treatment, including breast cancer. However, a better understanding of their mechanisms of action, increase evidence of safety and efficacy, and the implications of its use as a systemic therapy must be examined in more depth. This review provides a summary of oncolytic virotherapy in the context of breast cancer, both in the pre-clinical and clinical setting.
在过去几年中，免疫疗法彻底改变了肿瘤学领域，这主要得益于免疫检查点抑制剂引入临床常规治疗。尽管这些药物最近已获批用于治疗三阴性乳腺癌，但大多数乳腺癌患者无法从免疫疗法中获益，因为大多数肿瘤不被认为具有免疫反应性。因此，必须制定新策略，使免疫疗法更接近乳腺癌患者。溶瘤病毒引入免疫肿瘤学领域已在癌症治疗（包括乳腺癌）中显示出有前景的结果。然而，必须更深入地研究对其作用机制的更好理解、增加安全性和有效性的证据以及作为全身治疗使用的影响。本综述总结了乳腺癌临床前和临床环境中溶瘤病毒疗法的情况。
